Business Context and Reporting Period
This Form 8-K is a Current Report filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 1, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report primarily serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses on operational milestones rather than financial statement updates.
Material Changes and Operational Milestones
- Operational Target Exceeded: The Company announced it exceeded its procedural target of 1,500 patient cases for the year 2021.
- Regulatory Status: The information provided is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing includes standard disclaimers that the furnishing of information under Item 7.01 does not constitute a determination by the Company that the information is material or required by Regulation FD. No specific forward-looking guidance, risk factors, or contingencies are detailed in this specific text excerpt.
Investor Verification Checklist
- Verify the actual number of patient cases achieved in 2021 by reviewing the attached Exhibit 99.1 (Press Release), as the 8-K text only confirms the target was exceeded.
- Confirm the Company's current financial health (revenue, cash position) by reviewing the most recent 10-Q or 10-K, as this 8-K contains no financial metrics.
- Check for any subsequent updates or press releases, given the Company's explicit statement that it is under no obligation to update this information.